In value terms, M&A activity in Canada increased by 6187% in Q2 2023 compared with the previous quarter’s total of $33.4m and fell by 8% as compared to Q2 2022. Related deal volume increased by 46% in Q2 2023 versus the previous quarter and was 36% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Canada in Q2 2023 were Centerview Partners; FOS Advisors; NG Holdings Canada with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in Canada Q2 2023 were Fasken Martineau DuMoulin; Morgan, Lewis & Bockius; Stikeman Elliott with 4, 3, 3 deals respectively.
For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
Source link
#activity #pharmaceutical #industry #Canada #increased
